baber/WOPTO huggingface dataset:
Patent NZ-528936-A (NZ)
Title: Pharmaceutical products, preparation and uses thereof
Inventor: TOBYN MICHAEL JOHN
IPC: A61K38/00
Filed: 2002-04-09
Abstract: Disclosed is: 1) an oral dosage form comprising at least one therapeutic agent in crystalline form said dosage form comprising at least one reticulated three-dimensional microstructure comprising: a network of substantially interconnecting walls, said walls being provided; and a multiplicity of pores defined by said substantially interconnecting walls. 2) the use of at least one reticulated three-dimensional microstructure as a physiologically acceptable support for crystals of a therapeutic agent, which reticulated microstructure comprises: a network of substantially interconnecting walls, said walls being provided by a multiplicity of crystals arranged to at least partially abut each other, said crystals defining said walls comprising crystals of a physiologically acceptable support material; and a multiplicity of pores defined by said substantially interconnecting walls. 3) a process of preparing an oral dosage form as defined in any of claims 1 to 20, which process comprises: forming an emulsion comprising (i) a first phase, (ii) a second phase substantially immiscible with said first phase, and (iii) at least one surfactant; which first phase defines a network of substantially interconnected emulsion channels and comprises a solution comprising at least one therapeutic agent; allowing at least crystals of said at least one therapeutic agent to form in said emulsion channels, whereby a multiplicity of crystals are formed so as to at least partially abut each other so as to be capable of forming the walls of at least one three-dimensional reticulated microstructure; and recovering said crystals from said emulsion.
Patent NZ-529046-A (NZ)
Title: Quinoline derivative having azolyl group and quinazoline derivative
Inventor: KUBO KAZUO
IPC: A61P19/02
Filed: 2002-04-26
Abstract: Quinoline derivatives and quinazoline derivatives of formula (Ia) and pharmaceutically acceptable salts or solvates thereof, which have a strong antitumor activity, are disclosed, wherein: X represents CH or nitrogen; R15 and R16 represent C1-6alkoxy; R17, R18, R19 and R20 are as defined in the specification; and R21 represents optionally substituted azolyl as defined in the specification.
Patent NZ-531809-A (NZ)
Title: Water current turbine sleeve mounting
Inventor: FRAENKEL PETER
IPC: F03B17/06
Filed: 2004-03-18
Abstract: A water current flow actuable turbine installation including at least one column upstanding from a river or the sea bed to project above the water level for supporting at least one water current turbine wherein in order to accommodate change of direction of water flow with respect to the water turbines arrangements are provided to enable selective control of the operational pitch of the blades of the rotor of each turbine with respect to the direction of water flow with respect to such turbines. (62) Divided out of 514274
Patent NZ-533383-A (NZ)
Title: Aqueous oxaliplatin formulations stabilised by lactic acid or lactic acid derivatives
Inventor: LAURIA SARA
IPC: A61K31/555
Filed: 2002-11-22
Abstract: Disclosed is a stable oxaliplatin solution formulation comprising a formulation selected from the group consisting of: oxaliplatin, an effective stabilizing amount of lactic acid and a pharmaceutically acceptable carrier; or oxaliplatin, an effective stabilising amount of a pharmaceutically acceptable salt of lactic acid, and a pharmaceutically acceptable carrier; or oxaliplatin, an effective stabilising amount of lactic acid and a pharmaceutically acceptable salt of lactic acid, and a pharmaceutically acceptable carrier. Also disclosed is the use of the disclosed formulation in the treatment of cancer and a method of stabilising oxaliplatin by adding lactic acid.
Patent NZ-533545-A (NZ)
Title: N-Heteroarylnicotinamide derivatives
Inventor: MIO SHIGERU
IPC: A01N43/836
Filed: 2002-11-19
Abstract: Disclosed are compounds of the formula (I); wherein R represents a C1-C6 alkyl group which may be substituted with halogen atom(s); R1 represents a hydrogen atom, a C1-C6 alkyl group which may be substituted with substituent(s) selected from the following substituent group A, a C2-C6 alkenyl group or an acyl group; X represents CR2 or an N atom; And the other substituents are described in the specification. Further disclosed is a process for their production and a pesticide containing compounds of formula (I) as active ingredient.
Patent NZ-538993-A (NZ)
Title: Method for the synthesis of a bifunctional complex
Inventor: FRESKGARD PER-OLA
IPC: C12N15/10
Filed: 2003-10-30
Abstract: A method for obtaining a bifunctional complex comprising a display molecule part and a coding part, wherein a nascent bifunctional complex comprising a chemical reaction site and a priming site for enzymatic addition of a tag is reacted at the chemical reaction site with one or more reactants, and provided with respective tag(s) identifying the reactants(s) at the priming site using one or more enzymes.
Patent NZ-539059-A (NZ)
Title: Use of (R)-verapamil for the treatment of abnormal increases in gastrointestinal motility
Inventor: DEVANE JOHN
IPC: A61P1/06
Filed: 2002-11-15
Abstract: Disclosed is the use of a therapeutically effective amount of enriched (R) - verapamil in the manufacture of a medicament for the treatment of an abnormal increase in gastrointestinal motility.
Patent NZ-539849-A (NZ)
Title: Infant formula containing CMP, UMP, GMP, IMP and AMP
Inventor: BURGHER ANITA MARIA
IPC: A23L1/30
Filed: 2003-10-08
Abstract: Disclosed is an infant formula composition for administration to preterm infant containing nucleotides in the following amounts: 3.2mg/L to 15.4 mg/L of CMP (cytidine monophosphate), 1.8 mg/L to 11.0 mg/L of UMP (uridine monophosphate), 1.8 mg/L to 8.0 mg/L of GMP (guanosine monophosphate), 0.1 mg/L to 2.2 mg/L of IMP (inosine monophosphate), 2.5mg/L to 13.2 mg/L of AMP (adenosine monophosphate). The above described formula may also be in the form of a concentrate liquid or powder which may be mixed with water to make a form for feeding.
Patent NZ-539861-A (NZ)
Title: Impact driver and fastener removal device in two pieces with upper member able to be struck so as to drive lower member into fastener without damage to lower member
Inventor: KOZAK BURTON
IPC: B25B13/50
Filed: 2005-05-06
Abstract: A fastener impact driver device 10 includes a fastener engagement member 12 having a plurality of projections (not shown) disposed about a lower portion 16 that engages a corresponding peripheral portion 18 of a fastener 20. The device 10 further includes a positioning member 22 having an upper portion 24 that ultimately receives a force thereupon, and a lower portion 26 that engages a cooperating upper portion 28 of the fastener engagement member 12 whereby a force such a hammer strike is imparted upon the upper portion 24 of the positioning member 22 to drive the projections 14 of the fastener engagement member 12 into the head 44 of the fastener 20 without damage of the fastener engagement member 12, whereupon the positioning member 22 is removed from the fastener engagement member 12 and a hand tool is removably secured to the fastener engagement member 12 to impart rotary motion to the member 12 and the fastener 20 thereby removing the fastener 20 from or urging the fastener 20 into a workpiece.
Patent NZ-541353-A (NZ)
Title: Extended particle size distribution ceramic fracturing proppant
Inventor: WEBBER ROY A
IPC: C04B35/185
Filed: 2004-01-20
Abstract: A proppant mixture with an extended particle size distribution that exhibits improved properties, such as crush strength and conductivity, as compared with a conventional product with a narrow size distribution is disclosed. A method of forming a proppant mixture comprising combining a particulate material with a liquid to form a mixture is also disclosed. These proppant mixtures are useful in oil and gas wells and are also suited to the extraction of other fluids from boreholes, such as water wells.
Patent NZ-548331-A (NZ)
Title: Porous bodies and method of production thereof
Inventor: COOPER ANDREW IAN
IPC: C08J9/16
Filed: 2005-01-28
Abstract: Check later The disclosure relates to a method for preparing water dispersible or water soluble porous bodies and the bodies themselves. These porous bodies have an intrusion volume as measured by mercury porosimetry of at least about 3 ml/g and comprise a three dimensional open-cell lattice containing less than 10% by weight of a water soluble polymeric material and 5 to 90% by weight of a surfactant, and a hydrophobic material incorporated into the lattice to be dispersed when the surfactant dissolves, with the proviso that said porous bodies are not spherical beads having an average bead diameter of 0.2 to 5mm.; The method comprises the steps of: (a) providing an intimate mixture of the polymeric material and the surfactant in a liquid medium (b) providing a fluid freezing medium at a temperature effective for rapidly freezing the liquid medium; (c) cooling the liquid medium with the fluid freezing medium at a temperature below the freezing point of the liquid medium for a period effective to rapidly freeze the liquid medium; and (d) freeze-drying the frozen liquid medium to form the porous bodies by removal of the liquid medium by sublimation.
Patent NZ-550369-A (NZ)
Title: Combinations of glycopyrrolate and beta2 adrenoceptor agonists
Inventor: COLLINGWOOD STEPHEN PAUL
IPC: A61K31/402
Filed: 2005-05-17
Abstract: Disclosed is a medicament comprising, separately or together: (A) glycopyrrolate; and (B) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one in free or salt or solvate form, for simultaneous or sequential administration in the treatment of chronic obstructive pulmonary disease. Particularly preferred forms of compound (B) are (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate and (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one hydrochloride.
Patent NZ-551160-A (NZ)
Title: Fixing appliance with internal combustion engine with regulating thermistor
Inventor: TOULOUSE BRUNO
IPC: B25C1/08
Filed: 2005-05-26
Abstract: A temperature sensitive thermistor 12 is mounted on a printed circuit board 10 close to an electrical motor 8 and transmits temperature information to a management module 15 also mounted on the board. The board itself is mounted on the motor 8 which is positioned within the cylinder head of an internal combustion engine chamber to drive a fan which serves to mix gases, empty exhaust and cool the cylinder and piston. The management module 15 controls the operation of the motor 8 partially in response to the temperature sensed by the thermistor 12.
Patent NZ-553690-A (NZ)
Title: Manipulation of flavonoid biosynthesis in plants (4) and isolated nucleic acids encoding dihydrolflavonol 4-reductase
Inventor: SPANGENBERG GERMAN
IPC: C12N15/55
Filed: 2002-10-04
Abstract: A substantially purified or isolated nucleic acid encoding dihydroflavonol 4-reductase (DFR) and its polypeptide from a clover (Trifolium) or ryegrass (Lolium) species are described. Vectors and plant cells comprising the nucleic acid are described. The nucleic acid can be introduced into a plant to modify flavonoid biosynthesis, protein binding, metal chelation, anti-oxidation, UV-light absorption, pigment production, plant defense to biotic stress or forage quality, or can be used as a molecular marker.
Patent NZ-554655-A (NZ)
Title: Rotary bearing support for a rotatable pressure vessel
Inventor: LEE OLAF L
IPC: B01J3/03
Filed: 2004-09-21
Abstract: A rotatable pressure vessel 100 having a rotational drive means and support frame, the elongated pressure vessel 100 having an enclosed volume of about 30 to about 90 m3 capable of maintaining an internal pressure of about 10 to 4200 kPa, a relative humidity of up to about 100% relative humidity and a temperature of about 20 to 200°C, the vessel comprising a support end B and a driven end A, the driven end A comprising means 106 to rotate the vessel about a longitudinal axis, the support end B in contact with the support frame 111, the interface between the support frame 111 and the support end B comprising a bearing for supporting the load of the vessel.
Patent NZ-555817-A (NZ)
Title: Apparatus and method for controlling vessel changeover in a continuous process
Inventor: MURDOCH BRETT WILLIAM
IPC: B67D3/00
Filed: 2007-06-12
Abstract: A process control method and processing unit for reducing product loss during vessel changeover in a continuous process, with particular application to the dairy industry, are disclosed. The unit includes at least two vessels (silo 1, 2), a holding vessel into which the vessels drain via separate draining mechanisms, at least one surge restrictor valve (3a, 3b) that is capable of controlling flow of a fluid from each vessel, isolation valves (7a, 7b) between the surge restrictor valves and the draining mechanisms, and at least one discharge pump (8a, 8b) which transports fluid from the holding vessel to the process stream. The surge restrictor valve is sized to maintain a velocity of at least 1.5 metres/second from the vessels to the holding vessel. The first vessel empties fluid to the holding tank through the surge restrictor valve and when the first vessel fluid level reaches a predetermined level a control system opens the isolation valve (7b) from the second vessel. The surge restrictor halts backflow via the draining mechanism due to gravity from the second vessel to the first vessel. The control system then closes the isolation valve from the first vessel.
Patent NZ-567774-A (NZ)
Title: Enzyme and methodology for the treatment of a biomass
Inventor: THOMPSON VICKI S
IPC: C12N1/21
Filed: 2006-10-31
Abstract: Disclosed is an isolated or purified hemicellulase or xylanase enzyme of Alicyclobacillus acidocaldarius ATCC 27009, wherein the enzyme displays optimum enzymatic hemicellulase or xylanase activity at a temperature of greater than about 80°C, and at a pH of less than about 2, and wherein the enzyme is water soluble. Also disclosed is the use of the said enzyme in a method for the treatment of a biomass.
Patent NZ-571970-A (NZ)
Title: Recombinant attenuated clostridium organisms and vaccine
Inventor: COCHRAN MARK D
IPC: A61K39/08
Filed: 2007-04-12
Abstract: Disclosed is a nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin. The mutein alpha-toxin comprises an amino acid sequence as defined in the complete specification minus at least 9 consecutive amino acid residues; with no more than 48 consecutive amino acid residues deleted; and wherein one of the deleted amino acid residues is His68.
Patent NZ-573233-A (NZ)
Title: A friction pivot joint and window stay
Inventor: DAVIS PAUL
IPC: E05D7/00
Filed: 2008-11-27
Abstract: An arm 4, typically for supporting a pivoted window sash, is pivotally connected typically to a frame or sash plate 1 via a pivot bearing formed from an annular boss 6 of arm 4 being located within aperture 9 of plate 1. Arm 1 has an annular wall surrounding aperture 9 which projects inwardly then turns at an annular step to terminate as a generally cylindrical portion. A wear resistant plastic bush has a sleeve 7 located between aperture 9 and boss 6 and a flange 8 placed within the bearing and the free end of the boss is pressed over to form the bearing.
Patent NZ-575574-A (NZ)
Title: Valve assembly for inflatable bodies having a vent body defining an external and internal orfice
Inventor: NICKERSON L
IPC: A47C27/08
Filed: 2007-09-18
Abstract: Disclosed is an intra-chamber valve assembly for use with an inflatable body defining a fluid impermeable, pressurizable chamber and an orifice for exposing the chamber to an ambient environment. The assembly includes a vent body which has an external orifice for exposure to the ambient environment, an internal orifice in fluid communication with the external orifice for presenting to the chamber and an inflatable body interface adapted to sealingly occupy the inflatable body orifice. The assembly includes a collapsible, hollow elongate member with a proximal end extending from the internal orifice of the vent body and which terminates at a distal end. Air directly travels in a straight through path from the external orifice to the distal end. A first compression member oriented about the elongate member at a first location so as to sealingly collapse the elongate member upon presentation of a sufficient mechanical force. The elongate member is wholly disposed within the chamber defined by the inflatable body when the valve assembly is associated therewith.
Patent NZ-580180-A (NZ)
Title: Klotho-beta
Inventor: DESNOYERS LUC
IPC: A61K38/17
Filed: 2008-04-01
Abstract: Disclosed are uses of anti-KLBeta agents, and detection of KLBeta and/or FGF19 and/or FGFR4 for treating cancer, liver disorders, wasting syndrome and obesity related diseases.
Patent NZ-584274-A (NZ)
Title: A high voltage transformer with high and low voltage coils, with the low voltage coil between two subsets of coils in the high voltage coil
Inventor: HANSSON MIKAEL
IPC: H01F3/14
Filed: 2007-12-17
Abstract: Disclosed is a high voltage transformer (500). The transformer comprises a core (501), a high voltage coil (520) on the core, and a low voltage coil (510) on the core. The core comprises a pair of E cores (502, 503) forming a centre leg and two outer legs, each outer leg with an air gap between opposing legs of the E cores. The low voltage coil and the high voltage coil are on the centre leg. The high voltage coil comprises two subsets of coils, and the low voltage coil is placed between the subsets so they are kept apart. There is a distance from the low voltage coil to the air gaps. (62) Divided Out of 578449
Patent NZ-586263-A (NZ)
Title: 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
Inventor: VON NUSSBAUM FRANZ
IPC: A61K31/505
Filed: 2008-12-09
Abstract: Disclosed is a compound of the formula (I) e.g. (rac)-Ethyl4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4 tetrahydropyrimidine-5-carboxylate , in which the variables are defined in the specification or a salt, a solvate or a solvate of a salt thereof for the treatment and/or prevention of pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), or chronic-obstructive pulmonary diseases (COPD), of acute lung injury (ALI), of acute respiratory distress syndrome (ARDS), of pulmonary emphysema, of alpha-1 antitrypsin deficiency (AATD) and of cystic fibrosis (CF).
Patent NZ-587642-A (NZ)
Title: Antimicrobial composition comprising honey and a metal chelator compound
Inventor: GANNABATHULA SWAPNA
IPC: A23L21/25
Filed: 2011-08-29
Abstract: Use of a composition in the manufacture of a medicament to inhibit yeast growth (wherein the yeast is from the genus Candida particularly a strain of Candida albicans), wherein the composition includes:a therapeutically effective amount of lactoferrin; anda therapeutically effective amount of either: (a) at least one active honey; or (b) at least one bioactive fraction of active honey wherein the monosaccharides of the honey have been removed; or (c) at least one honey analogue containing monosaccharides, water and either or both of DHA and MGO and having at least one further characteristic being: a pH of 3.0 to 5.0; hydrogen peroxide; phenolics characteristic of active honeys; bee defensins; catalase enzyme; a water activity less than 0.7; or (d) combinations of the honey, the honey fraction and the honey analogue,wherein active honey refers to a honey with an antimicrobial activity in the absence of hydrogen peroxide referred to interchangeably as a honey containing UMF activity, MGO activity or containing DHA compound.
Patent NZ-600768-A (NZ)
Title: Human antibodies to human angiopoietin-like protein 4
Inventor: KIM JEE H
IPC: C07K16/22
Filed: 2010-12-23
Abstract: Disclosed is an isolated human antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-like protein 4 (hANGPTL4), comprising three heavy chain complementarity determining regions, HCDR1, HCDR2, and HCDR3, and three light chain complementarity determining regions, LCDR1, LCDR2, and LCDR3, wherein the amino acid sequences of the HCDR1, HCDR2, and HCDR3 comprise SEQ ID NO: 28, 30 and 32, respectively, and the amino acid sequences of LCDR1, LCDR2, and LCDR3 comprise SEQ ID NO: 36, 38, and 40, respectively; wherein the sequences are as defined in the specification. Also disclosed is the use of such antibodies to treat ANGPTL4-mediated diseases in humans.
Patent NZ-606969-A (NZ)
Title: A method of treating alzheimer’s disease
Inventor: EPSHTEIN OLEG ILIICH
IPC: C07K16/40
Filed: 2011-07-15
Abstract: Disclosed is the use of: a) a homeopathic activated-potentiated form of an antibody to brain-specific protein S-100; and b) a homeopathic activated-potentiated form of antibodies to endothelial NO synthase in the manufacture of a combination medicament for the treatment of Alzheimer’s disease.
Patent NZ-610482-A (NZ)
Title: Predictors of patient response to treatment with egf receptor inhibitors
Inventor: WATSON DREW
IPC: C12P19/34
Filed: 2009-05-13
Abstract: Disclosed is a method for predicting a likelihood that a human patient with an EGFR-expressing colorectal cancer will exhibit a beneficial response to an EGFR inhibitor comprising: (a) measuring in a tumour sample obtained from the patient a level of CEACAM6 RNA transcript, or an expression product thereof; (b) determining a normalised expression level of the CEACAM6 transcript, or the expression product thereof relative to expression level of an RNA transcript or expression product, respectively, of a reference gene; and (c) determining a likelihood that the patient will exhibit a beneficial response to an EGFR inhibitor when the normalised expression level of CEACAM6 RNA transcript or the expression product thereof is about the same as a level thereof in a subject that responds to the EGFR inhibitor, or determining a likelihood that the patient will not exhibit a beneficial response to an EGFR inhibitor when the normalised expression level of the CEACAM6 RNA transcript or the expression product thereof is about the same as a level thereof in a subject that does not respond to the EGFR inhibitor.
Patent NZ-622953-A (NZ)
Title: Novel soft rock inhibitors
Inventor: LEYSEN DIRK
IPC: C07D417/12
Filed: 2012-08-31
Abstract: The present disclosure relates to compounds of formula I as defined in the specification as kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present disclosure relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the disclosure relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases and ophthalmic diseases.